Biologics Outsourcing Market Report 2026

The biologics outsourcing market size has grown rapidly in recent years. It will grow from $22.58 billion in 2025 to $25.57 billion in 2026 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to rising biologics commercialization activities, increasing capital intensity of biologics facilities, expansion of biosimilar development programs, growing complexity of regulatory compliance, increasing collaboration between pharma and cdmos.

The biologics outsourcing market size is expected to see rapid growth in the next few years. It will grow to $42.43 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to increasing demand for large-scale biologics production, rising investments in multi-product manufacturing sites, expansion of cell and gene therapy outsourcing, growing focus on supply chain resilience, increasing adoption of digital manufacturing platforms. Major trends in the forecast period include increasing strategic outsourcing of biologic manufacturing, rising demand for end-to-end outsourcing services, growing preference for flexible manufacturing partnerships, expansion of global cdmo networks, enhanced focus on cost and risk optimization.

The increasing incidence of cancer is anticipated to drive the growth of the biologics outsourcing market in the coming years. Cancer encompasses a wide range of diseases that can arise in almost any organ or tissue when abnormal cells grow uncontrollably, extend beyond their normal limits, and spread to other organs or invade surrounding tissues. Biologics outsourcing plays a crucial role in addressing cancer by offering specialized expertise, resources, and infrastructure for the development, manufacturing, and clinical supply of biologic therapies, such as monoclonal antibodies, immunotherapies, and other targeted biologics used in the diagnosis, treatment, and management of various cancers. For example, in January 2023, according to the National Center for Biotechnology Information, a US-based intergovernmental organization, there were 1,958,310 new cancer cases reported in the United States, with 609,820 cancer-related deaths projected for 2023. Additionally, the annual number of new cancer cases is expected to increase to 29.5 million, while cancer-related deaths are projected to reach 16.4 million by 2040. Consequently, the growing burden of cancer is fueling the expansion of the biologics outsourcing market.

Leading companies in the biologics outsourcing market are increasingly concentrating on developing new contract development and manufacturing organizations (CDMOs) to maintain their competitive position in the market. A contract development and manufacturing organization (CDMO) is an entity that supports pharmaceutical and biotechnology companies by offering a wide range of services related to the development and manufacturing of drugs and other therapeutic products. For example, in October 2023, Tanvex BioPharma USA Inc., a US-based biopharmaceutical developer and manufacturer, launched Tanvex CDMO. This newly established division delivers end-to-end biologics development and manufacturing services to meet the requirements of the biopharmaceutical industry. Situated in San Diego’s Sorrento Valley biotech hub, Tanvex CDMO operates from a 100,000-square-foot facility that includes an advanced Research and Development (R&D) center, two mammalian Good Manufacturing Practice (GMP) manufacturing suites, one microbial GMP manufacturing suite, Quality Control (QC) laboratories, and a GMP warehouse. Building on Tanvex BioPharma USA Inc.’s established expertise, Tanvex CDMO seeks to support early-stage companies in progressing mammalian- and microbial-derived biologics from initial concept through commercialization, thereby contributing significantly to the advancement of novel biologics and biosimilars.

In December 2023, Ajinomoto Co., Inc., a Japan-based biotechnology corporation, acquired Forge Biologics for an undisclosed amount. Through this acquisition, Ajinomoto seeks to broaden its global biologics outsourcing presence and strengthen its technological capabilities in cell and gene therapy development and commercial-scale manufacturing to better serve pharmaceutical and biotechnology clients. Forge Biologics is a US-based provider of outsourced biologics services, specializing in adeno-associated virus (AAV) vector development, gene therapy manufacturing from preclinical to commercial scale, and offering analytical and regulatory support services to biopharma companies.

Major companies operating in the biologics outsourcing market are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.

North America was the largest region in the biologics outsourcing market in 2025. The regions covered in the biologics outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologics outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the biologics outsourcing market by increasing costs of imported manufacturing equipment, raw materials, filtration systems, and electronic monitoring tools used by CDMOs. North America and Europe are significantly affected due to cross-border supply dependencies, while Asia-Pacific faces cost pressures on export-focused manufacturing. These tariffs are increasing production costs and influencing outsourcing location decisions. At the same time, they are supporting regional manufacturing expansion, domestic sourcing strategies, and long-term investments in localized biologics production capabilities.

The biologics outsourcing market research report is one of a series of new reports that provides biologics outsourcing market statistics, including biologics outsourcing industry global market size, regional shares, competitors with a biologics outsourcing market share, detailed biologics outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the biologics outsourcing industry. This biologics outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biologics outsourcing involves pharmaceutical companies collaborating with external vendors or contract manufacturing organizations (CMOs) to delegate different stages of biologic drug development, production, and supply chain operations. It is utilized in the pharmaceutical industry for various objectives associated with the development, manufacturing, and supply chain management of biological drugs.

The primary product types in biologics outsourcing include antibodies, recombinants, vaccines, proteins, and others. Antibodies are immune system-derived defense proteins that are generated in response to the presence of foreign substances known as antigens. The different sources comprise human, microbial, and others, and they are utilized across oncology, cellular and gene therapy, blood and blood-related product development, vaccine development, stem cell research, and other applications by various end users such as pharmaceutical companies, biotechnology firms, and contract development and manufacturing organizations (CDMOs).

The biologics outsourcing market includes revenues earned by entities through cell line development, contract research services, and optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.